The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia

(2014) S. P. Treon et al.   BLOOD

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease

(2013) Rakesh Bam et al.   AMERICAN JOURNAL OF HEMATOLOGY

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia

(2013) G. Yang et al.   BLOOD

MYD88 L265P mutation in Waldenstrom macroglobulinemia

(2013) S. Poulain et al.   BLOOD

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms

(2013) M. Varettoni et al.   BLOOD

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

(2013) Z. R. Hunter et al.   BLOOD

MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

(2013) L. Xu et al.   BLOOD

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia

(2013) C Jiménez et al.   LEUKEMIA

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

(2012) Y.-T. Tai et al.   BLOOD

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

(2012) B. R. Davies et al.   MOLECULAR CANCER THERAPEUTICS

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome

(2011) D. H. McDermott et al.   BLOOD

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome

(2011) L. Dotta et al.   CURRENT MOLECULAR MEDICINE

Site-specific Phosphorylation of CXCR4 Is Dynamically Regulated by Multiple Kinases and Results in Differential Modulation of CXCR4 Signaling

(2010) John M. Busillo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

AMD3100 is a potent antagonist at CXCR4R334X, a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome

(2010) David H. McDermott et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Inhibitor hijacking of Akt activation

(2009) Tatsuya Okuzumi et al.   Nature Chemical Biology

SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia

(2008) H. T. Ngo et al.   BLOOD

Targeting NF- B in Waldenstrom macroglobulinemia

(2008) X. Leleu et al.   BLOOD